PET scans probe link between brain inflammation and Alzheimer's damage
NCT ID NCT05911178
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This study uses advanced PET scans to investigate how brain inflammation and tau protein buildup affect synaptic density in people with Alzheimer's disease. Researchers will compare Alzheimer's patients to healthy controls over two years, tracking changes in these brain markers. The goal is to better understand the disease's progression and refine patient subgroups for future treatment trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- PET tracers ([11C]-UCB-J, [18F]-DPA-714, [18F]-RO-948, [11C]-PiB) used for brain imaging
- What this could lead to
- Could help identify distinct Alzheimer's subtypes based on brain inflammation and tau patterns, leading to more targeted treatments.
- What could go wrong
- This is an observational imaging study, not a treatment trial. It may not directly lead to new therapies, and results may not apply to all Alzheimer's patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
90 people
The number who actually took part.
- Started
-
Oct 2023
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: General Inclusion Criteria: * Adult (older than 18 years) * Women old enough to procreate under effective contraception * Signed consent * Absence of general or systemic disorders that may interfere with cognition. Inclusion criteria for EOAD and LOAD patients: * Progressive amnestic syndrome, associated or not with other cognitive impairments, * CDR = 0.5 or 1 * Absence of general or systemic disorders that may interfere with cognition or PET imaging analysis, * Absence of brain lesions as determined by MRI carried out within the framework of usual care. * Presence of CSF biomarkers profile suggestive of AD Inclusion criteria for controls: * absence of subjective problems with memory and normal scores on the MMSE (MMSE \> 27) with no more than one word missing. * older than 50 years old. * Scores on the Free and Cued Selective Reminding Test (FCSRT) of \>25 for free recall and \>44 for total recall. * absence of general or systemic disorders that may interfere with cognition at follow-up. Controls will be matched to AD patients for age and education level. Exclusion Criteria: * Subject with a psychiatric evolutionary and/or poorly checked pathology (left to the judgement of the investigator). * Subject with a grave, severe or unstable pathology (left to the judgement of the investigator) the nature of which can interfere with the variables of evaluation. * Current auto-immune disease * Subject presenting contraindications to the 3T MRI * Known or supposed histories (≤5 years) of severe alcoholism or misuse of drugs * Vascular, inflammatory or expansive, visible lesion in the MRI which can interfere on the criteria of diagnosis. * No health insurance * Pregnant, breast-feeding woman or planning a pregnancy in two years of follow-up. * Diagnosis or history of other possible etiology of dementia, including but not limited to other neurodegenerative disorders. * Person placed under the protection of justice * Patient under guardianship or curatorship
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Lille
Lille, France
-
CHU de Rouen
Rouen, France
-
GHU Saint Anne Psychiatrie & Neurosciences
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glutathione, brain metabolism and inflammation in Alzheimer's disease
- Can an experimental infusion reach the brain to fight Alzheimer's?
- A new roadmap to predict Alzheimer's before memory fails
- Can a 500-Person study unlock Alzheimer's early signs?
- AI hunts for early clues to Parkinson's and Alzheimer's progression
- Can a daily supplement slow early Alzheimer's memory decline?